Robert J. van Soest - Concepedia

Author

Robert J. van Soest

Erasmus MC Cancer Institute ORCID

Also Known As

R. Van Soest, R.J. Van Soest, R.J. van Soest, Robert J van Soest, Robert J. van Soest, Robert van Soest

Publications

1.2K

Citations

H-Index

Concepts

All Affiliations

Erasmus MC Cancer Institute Erasmus MC Sint Franciscus Gasthuis Elisabeth-TweeSteden Ziekenhuis Johns Hopkins University

About

Robert J. van Soest is an author at Erasmus MC Cancer Institute specializing in urology, medicine, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	733
2	Pharmacology	4	4	633
3	Cancer Therapeutics	3	3	430
4	Pathology	1	1	32
5	Surgical Oncology	1	1	10

Robert J. van Soest

Publications

Citations

H-Index

Page 1

	Year	Citations
Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells Wendy Onstenk, Anieta M. Sieuwerts, Jaco Kraan, European Urology UrologyOncologyGenitourinary CancerMedicineCirculating Tumor Cells	2015	237
Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer Robert J. van Soest, Martin E. van Royen, Ellen S. de Morrée, European Journal of Cancer UrologyOncologyMedicinePharmacotherapyAnti-cancer Agent	2013	203
Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: data from two randomized phase III trials Robert J. van Soest, Arnoud J. Templeton, Francisco Vera-Badillo, Annals of Oncology	2014	138
Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer Robert J. van Soest, Ellen S. de Morrée, Charlotte F. Kweldam, European Urology UrologyMedicinePharmacologyPharmacotherapyCastration-resistant Prostate Cancer	2014	130
Loss of SLCO1B3 drives taxane resistance in prostate cancer Ellen S. de Morrée, René Böttcher, Robert J. van Soest, British Journal of Cancer	2016	64
The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer Robert J. van Soest, Annemieke J.M. Nieuweboer, Ellen S. de Morrée, European Journal of Cancer UrologyOncologyMedicinePharmacotherapyAnti-cancer Agent	2015	63
Initial Biopsy Gleason Score as a Predictive Marker for Survival Benefit in Patients with Castration-resistant Prostate Cancer Treated with Docetaxel: Data from the TAX327 Study Robert J. van Soest, Ellen S. de Morrée, Liji Shen, European Urology Survival BenefitUrologyGenitourinary CancerTax327 StudyMedicine	2013	58
Understanding taxanes in prostate cancer; importance of intratumoral drug accumulation Ellen de Morrée, Robert J. van Soest, Ashraf Aghai, The Prostate	2016	36
Prognostic factors in men with metastatic castration-resistant prostate cancer treated with cabazitaxel Bodine P.S. Belderbos, Ronald de Wit, Esther Oomen‐de Hoop, Oncotarget	2017	32
Associations between AR-V7 status in circulating tumour cells, circulating tumour cell count and survival in men with metastatic castration-resistant prostate cancer Bodine P.S. Belderbos, Anieta M. Sieuwerts, Esther Oomen‐de Hoop, European Journal of Cancer Ar-v7 StatusUrologyTumour Cell CountGenitourinary CancerMedicine	2019	32

Page 1